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Tumor-specific T lymphocytes can be regarded as a highly
effective mechanism for tumor rejection. A substantial
number of T-cell defined tumor antigens including
mutated oncoproteins and differentiation antigens have
been identified. However, while most spontaneous
tumors appear to be antigenic, few are immunogenic.
Activation of tumor-specific cytotoxic T cells (CTL)
requires presentation of tumor antigens by professional
antigen presenting cells (APCs) via MHC I molecules. Due
to their crucial role in T-cell activation, APCs are being
exploited for active cancer immunotherapy. Present exper-
imental strategies include the incubation of dendritic cells
with synthetic, tumor specific peptides to achieve uptake
of tumor antigens and presentation in the context of MHC
molecules. Alternatively, gene therapeutic approaches are
aimed at the endogenous expression of tumor antigens in
APCs upon transfer of suitable vector constructs.
Our strategy for the presentation of tumor antigens by
APCs is based on the intracellular delivery of tumor anti-
gens as part of a fusion protein specifically targeted to APC
cell surface receptors. We have constructed prototype mol-
ecules that contain a soluble fragment of CTLA-4 for cell
binding via interaction with B7 molecules, genetically
fused to a protein fragment derived from the tumor-asso-
ciated antigen ErbB2. To improve uptake and direct the
antigenic determinant preferentially to the MHC class I
pathway, in one of these protein vaccines also the translo-
cation domain of the bacterial Pseudomonas exotoxin A
has been included. In the parental toxin this protein
domain facilitates escape from the endosomal compart-
ment to the cytosol upon receptor mediated endocytosis.
Here we have investigated the in vitro cell binding activity
of such reagents and their antitumoral activity in immu-
nocompetent murine model systems. Specific binding to
B7 molecules and uptake of bacterially expressed protein
vaccines could be demonstrated. Ex vivo restimulation
with an ErbB2-derived peptide of splenocytes from Balb/c
mice injected with the fusion proteins resulted in
enhanced IFN-γ production by T cells. Protective and ther-
apeutic effects of ErbB2 protein vaccines were also investi-
gated. Vaccinated animals were protected against
subsequent challenge with syngeneic ErbB2 expressing
tumor cells. Likewise, s.c. injection of ErbB2 protein vac-
cines in the vicinity of established tumors resulted in
tumor rejection and long lasting protection indicating
that immunological memory was induced.
Our results suggest that chimeric proteins combining a
tumor antigen and specific recognition of APCs in a single
molecule are suitable for targeted delivery of antigens to
professional APCs and might become valuable tools for
cancer immunotherapy.
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